Economic evaluation of high-dose (80 mg/day) atorvastatin treatment compared with standard-dose (20 mg/day to 40 mg/day) simvastatin treatment in Canada based on the Incremental Decrease in End-Points Through Aggressive Lipid-Lowering (IDEAL) trial

Canadian Journal of Cardiology

Volumn 25, Issue 11, 2009, Pages

  Wagner, Monika ^a   Lindgren, Peter ^b   Merikle, Elizabeth ^c   Goetghebeur, Mireille ^a   Jönsson, Bengt ^b  

^a BioMedCom Consultants   (Canada)

^b European Health Economics   (Sweden)

^c PFIZER INC   (United States)

Author keywords

Atorvastatin; Clinical outcomes; Cost utility; Cost effectiveness; Markov model; Simvastatin

Indexed keywords

ATORVASTATIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN;

ABSENTEEISM; ADULT; AGED; ANGINA PECTORIS; ARTICLE; CANADA; CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DRUG COST; DRUG MEGADOSE; DRUG USE; FEMALE; FOLLOW UP; HEALTH CARE UTILIZATION; HEART ARREST; HEART FAILURE; HEART INFARCTION; HEART TRANSPLANTATION; HOSPITAL COST; HOSPITALIZATION; HUMAN; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; PERCUTANEOUS CORONARY INTERVENTION; PROBABILITY; PRODUCTIVITY; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; STROKE; SURVIVAL RATE; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; CANADA; CARDIOVASCULAR DISEASES; CONFIDENCE INTERVALS; COST OF ILLNESS; COST-BENEFIT ANALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HEALTH CARE COSTS; HEPTANOIC ACIDS; HOSPITALIZATION; HUMANS; HYPERLIPIDEMIAS; HYPOLIPIDEMIC AGENTS; MALE; MARKOV CHAINS; MIDDLE AGED; MYOCARDIAL INFARCTION; PROBABILITY; PYRROLES; RISK ASSESSMENT; SIMVASTATIN; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 70549111238     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0828-282X(09)70159-X     Document Type: Article

References (41)

1. Chow CM, Donovan L, Manuel D, Johansen H, Tu JV. Regional variation in self-reported heart disease prevalence in Canada. Can J Cardiol 2005;21:1265-1271 (Pubitemid 43174606)
2. Heart and Stroke Foundation of Canada. The Growing Burden of Heart Disease and Stroke in Canada 2003. Ottawa: Heart and Stroke Foundation of Canada, 2003.
3. Manuel DG, Leung M, Nguyen K, Tanuseputro P, Johansen H. Burden of cardiovascular disease in Canada. Can J Cardiol 2003;19:997-1004.
4. Alter DA, Stukel TA, Newman A. Proliferation of cardiac technology in Canada: A challenge to the sustainability of Medicare. Circulation 2006;113:380-387 (Pubitemid 43803199)
5. Hall RE, Tu JV. Hospitalization rates and length of stay for cardiovascular conditions in Canada, 1994 to 1999. Can J Cardiol 2003;19:1123-1131
6. Genest J, Frohlich J, Fodor G, McPherson R. Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: Summary of the 2003 update. CMAJ 2003;169:921-924
7. McPherson R, Frohlich J, Fodor G, Genest J; Canadian Cardiovascular Society. Canadian Cardiovascular Society position statement - recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. Can J Cardiol 2006;22:913-927 (Pubitemid 44596492)
8. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-1278
9. Pedersen TR, Faergeman O, Kastelein JJ, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: The IDEAL study: A randomized controlled trial. JAMA 2005;294:2437-2445 (Pubitemid 41627921)
10. Lindgren P, Graff J, Olsson AG, Pedersen TJ, Jonsson B. Cost-effectiveness of high-dose atorvastatin compared with regular dose simvastatin. Eur Heart J 2007;28:1448-1453 (Pubitemid 47343816)
11. Canadian Agency for Drugs and Technologies in Health. Guidelines for the economic evaluation of health technologies: Canada. 〈http://www.cadth. ca〉 (Version current at October 2, 2009).
12. Bata IR, Gregor RD, Wolf HK, Brownell B. Trends in five-year survival of patients discharged after acute myocardial infarction. Can J Cardiol 2006;22:399-404. (Pubitemid 43834012)
13. Yan RT, Yan AT, Tan M, et al. Age-related differences in the management and outcome of patients with acute coronary syndromes. Am Heart J 2006;151:352-359 (Pubitemid 43144736)
14. Alter DA, Chong A, Austin PC, et al. Socioeconomic status and mortality after acute myocardial infarction. Ann Intern Med 2006;144:82-93. (Pubitemid 46768226)
15. Petrella RJ, Merikle E, Jones J. Prevalence and treatment of dyslipidemia in Canadian primary care: A retrospective cohort analysis. Clin Ther 2007;29:742-750 (Pubitemid 47018270)
16. Nordic Classification Centre. Nordic Centre for Classifications in Health Care. NordDRG Users' Manual 2006. 〈http://www.nordclass.uu.se/verksam/ norddrgmanual/NordDRG-2006-SWE〉 (Version current at October 2, 2009).
17. Ontario Ministry of Health and Long-Term Care. Ontario Drug Benefit Formulary/Comparative Drug Index. 〈http://www.health.gov.on.ca/english/ providers/program/drugs/odbf-eformulary.html〉 (Version current at October 2, 2009).
18. Ontario Ministry of Health and Long-Term Care. Ontario Case Costing Initiative. 〈http://www.occp.com/〉 (Version current at October 2, 2009).
19. Statistics Canada. Table 5: the Consumer Price Index for Canada, major components and special aggregates (not seasonally adjusted), 1987-2006, 1992-100. 〈http://www.statcan.gc.ca/pub/62-001-x/00506/t/4125989-eng. htm〉 (Version current at October 2, 2009).
20. Statistics Canada. Earnings, average weekly, by province and territory. 〈http://www40.statcan.ca/l01/cst01/labr79.htm〉 (Version current at October 2, 2009).
21. Lindgren P, Stenestrand U, Hambraeus K, Wallentin L, Jonsson B. PCI reduces utility loss after MI in Sweden. Eur Heart J 2006;27(Suppl 1):773.
22. Bourgault C, Davignon J, Fodor G, et al. Statin therapy in Canadian patients with hypercholesterolemia: The Canadian Lipid Study - Observational (CALIPSO). Can J Cardiol 2005;21:1187-1193 (Pubitemid 43013529)
23. Russell MW, Huse DM, Miller JD, Kraemer DF, Hartz SC. Cost effectiveness of HMG-CoA reductase inhibition in Canada. Can J Clin Pharmacol 2001;8:9-16. (Pubitemid 33044165)
24. Grover SA, Coupal L, Paquet S, Zowall H. Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the secondary prevention of cardiovascular disease: Forecasting the incremental benefits of preventing coronary and cerebrovascular events. Arch Intern Med 1999;159:593-600. (Pubitemid 29133884)
25. Lindgren P, Jonsson B. Trial based economic evaluation of intensive atorvastatin compared to standard simvastatin in the IDEAL trial. 65th Annual Conference of the AHA. Tampa, May 11 to 14, 2006.
26. Mihaylova B, Briggs A, Armitage J, Parish S, Gray A, Collins R. Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: Economic analysis of a randomised trial in 20,536 individuals. Lancet 2005;365:1779-1785
27. Mihaylova B, Briggs A, Armitage J, Parish S, Gray A, Collins R. Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20,536 people. BMJ 2006;333:1145. (Pubitemid 44901435)
28. Szucs TD, Klose G, Dusing R. [Cost-effectiveness of atorvastatin for the prevention of coronary disease. An analysis of the ASCOT study.] Dtsch Med Wochenschr 2004;129:1420-1424
29. Glasziou PP, Eckermann SD, Mulray SE, et al. Cholesterol-lowering therapy with pravastatin in patients with average cholesterol levels and established ischaemic heart disease: Is it cost-effective? Med J Aust 2002;177:428-434 (Pubitemid 35402001)
30. Buller N, Gillen D, Casciano R, Doyle J, Wilson K. A pharmacoeconomic evaluation of the Myocardial Ischaemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study in the United Kingdom. Pharmacoeconomics 2003;21(Suppl 1):25-32. (Pubitemid 36332381)
31. Casciano R, Tarride JE, Breton MC, Stern L, Langer A. A pharmacoeconomic evaluation of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study in Canada. Can J Clin Pharmacol 2004;11:e179-90. (Pubitemid 46344883)
32. Gomez-Gerique JA, Casciano R, Stern L, Rejas J. A pharmacoeconomic evaluation of the effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes in Spain. Eur J Health Econ 2004;5:278-284 (Pubitemid 39382529)
33. Lange AP, Szucs TD. [Cost-effectiveness of atorvastatin in the early treatment of acute coronary syndromes in Germany based on the MIRACL study.] Med Klin (Munich) 2004;99:500-505
34. Olsson A, Casciano R, Stern L, Svangren P. A pharmacoeconomic evaluation of aggressive cholesterol lowering in Sweden. Int J Cardiol 2004;96:51-57 (Pubitemid 38760238)
35. Schwartz GG, Ganz P, Waters D, Arikian S. Pharmacoeconomic evaluation of the effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. Am J Cardiol 2003;92:1109-1112 (Pubitemid 37329539)
36. Huse DM, Russell MW, Miller JD, et al. Cost-effectiveness of statins. Am J Cardiol 1998;82:1357-1363
37. Elliott WJ, Weir DR. Comparative cost-effectiveness of HMG-CoA reductase inhibitors in secondary prevention of acute myocardial infarction. Am J Health Syst Pharm 1999;56:1726-1732
38. Grover SA, Ho V, Lavoie F, Coupal L, Zowall H, Pilote L. The importance of indirect costs in primary cardiovascular disease prevention: Can we save lives and money with statins? Arch Intern Med 2003;163:333-339
39. World Health Organization. Life tables for WHO Member states. 〈http://www.who.int/whosis/database/life-tables/life-tables.cfm〉 (Version current at October 2, 2009).
40. Ontario Ministry of Health and Long-Term Care. Ontario Guide to Case Costing. 〈http://www.occp.com/〉 (Version current at October 2, 2009).
41. Burstrom K, Johannesson M, Diderichsen F. Swedish population health-related quality of life results using the EQ-5D. Qual Life Res 2001;10:621-635 (Pubitemid 34056332)